CHERRY HILL, N.J., Sept. 21 /PRNewswire-FirstCall/ -- Nuvilex, Inc. (OTC Bulletin Board: NVLX), announced today that Legacy Biotechnologies, Inc., its joint venture partner with Reme-Flu(TM), will be incorporating Syn-X9(TM) proprietary delivery technology into Step 2 of the Reme-Flu(TM) protocol, a homeopathic remedy designed to help prevent and treat flu-type symptoms resulting from influenza-like illness, including swine flu.
The unique attributes of the Syn-X9(TM) technology, only available in Reme-Flu(TM), are designed to increase both speed of delivery and maximize bio-availability of the ingredients. The technology relies on all-natural compounds that envelope the liquid homeopathic tinctures, thereby providing an enhanced transport vehicle for the physiologically-active ingredients.
Certain homeopathic medicines work best in tincture potencies, and are best utilized by the body through sub-lingual absorption. Syn-X9(TM) technology is the perfect complement to help ensure optimal benefits from these fluid ingredients. An additional benefit from Syn-X9(TM) is that it can improve stability and therefore potency of the bio-actives contained in the tinctures. Syn-X9(TM) helps to ensure that Reme-Flu(TM) delivers superior benefits and allows Legacy Biotechnologies and Nuvilex to offer a uniquely developed homeopathic remedy that helps to prevent and lessen flu symptoms. The Syn-X9(TM) technology sets Reme-Flu(TM) apart from competing products in the marketplace.
Reme-Flu(TM) will soon be available for sale on Nutralegacy.com, one of the top-rated websites in the world, according to Alexa's global and well-known ranking system.
About Legacy Biotechnologies, Inc.
Legacy Biotechnologies, Inc. is an independent, privately owned firm specializing in the research and development of nutraceutical and cosmeceutical formulations. They specialize in creating innovative and cutting-edge compounds that address all facets of health. Its president, Steve Kushner, has been working in this field for over 26 years and has created several original formulas that have been marketed in the United States and abroad. Mr. Kushner's experience allows Legacy Biotechnologies, Inc. to excel at all phases of the health and nutrition industry. In addition to research and development, Legacy Biotechnologies, Inc. is also well versed in the manufacturing process, procurement of raw materials, creation of promotional material, and marketing of products.
About Nuvilex, Inc.
Nuvilex, Inc. is an emerging healthcare consumer products company. The Company's lead products include: Last Shot Hangover Remedy(TM), a unique sugar-free, calorie-free and caffeine-free liquid formula designed to ease the symptoms of a hangover; Cinnergen(TM), which promotes a healthy glucose metabolism; Cinnechol(TM), designed to help maintain normal cholesterol levels and support normal cardiovascular function; and Infinitink (R), a permanent yet more easily removable tattoo ink. The Company's complete portfolio spans aesthetics, dermatology, environmental and nutraceutical products, all of which are designed to directly or indirectly improve human health. In March 2009, Nuvilex merged with Freedom2 Holdings, Inc., the developer of Infinitink (R). In conjunction with the merger, the Company changed its name to Nuvilex, Inc. from eFoodSafety.com. Please visit www.nuvilex.com for additional information on the Company.
Safe Harbor Statement
Statements contained in this presentation that are not strictly historical are "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934. The forward-looking statements are made based on information available as of the date hereof, and the Company assumes no obligation to update such forward-looking statements. Forward-looking statements are sometimes identified by words such as "intends", "anticipates", "believes", "expects", and "hopes" and involve a number of risks and uncertainties that could cause the Company's actual results to differ materially from projected results. All parties are cautioned that such forward-looking statements involve risks and uncertainties that could cause the Company's actual results to differ materially from those in these forward-looking statements. Such risks and uncertainties include but are not limited to demand for the Company's products and services, the planned share exchange with Freedom2 Holdings, Inc., the Company's ability to secure additional financing, and other factors that may be more fully described in reports to shareholders and periodic filings with the Securities and Exchange Commission.
Company Contact: Blair Barnes Senior Vice President and Chief Financial Officer Nuvilex, Inc. Ph: 856-433-6088 Email: email@example.com Press Contact: Pat Arcand Arcand & Madison Ph: 617-576-7777 Email: firstname.lastname@example.org
|SOURCE Nuvilex, Inc.|
Copyright©2009 PR Newswire.
All rights reserved